“Black Lives Matter and BioCT is committed to addressing racism through members’ employment practices, their development of therapeutics to benefit all patients and our support of educational and job initiatives that promote inclusive economic opportunity,” BioCT said in a letter from the President and Board.
The same article in newhavenbiz reports on a Melinta bidding war and an Alexion patent settlement.